## CoNCERT Pharmaceuticals Inc.\*

Concert Pharmaceuticals Investor Relations Department 99 Hayden Avenue, Suite 500 Lexington, MA 02421 United States

Visit IR website ☐ Sign-up for Email alerts ☐

# NASDAQ: CNCE Last Trade: 16.09 Trade Time: 4:00 PM ET Oct 20, 2017 Change: -0.41 ♣ (-2.485%) Day Range 15.73 - 17.08 52-Week Range 7.11 - 19.11 Volume 445,962


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Company Profile**

At Concert Pharmaceuticals, we are pioneering our industryleading expertise in deuterium chemistry to discover and develop innovative drug products that have impact for patients and address important medical needs. Our innovative approach has already resulted in multiple drug candidates that offer improved ways to target a broad range of disease areas, including autoimmune and inflammatory diseases and central nervous system (CNS) disorders. Each of these novel candidates was designed to be improved with our deuterium chemistry, and is based on an approved drug, an advanced clinical candidate or a previously studied, biologically active compound.

(more)

### **Stock Performance**



### Press Releases [View all]

Oct 19, 2017

Concert Pharmaceuticals Announces PTAB

Denies Incyte Petition Challenging CTP-543

Patent

Aug 31, 2017

Concert Pharmaceuticals Announces
Webcast at Wells Fargo Healthcare
Conference

Aug 8, 2017

Concert Pharmaceuticals Reports Second

Quarter 2017 Financial Results and Provides

Company Update

Aug 1, 2017

Concert Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017

Jul 25, 2017

Vertex and Concert Pharmaceuticals
Complete Asset Purchase Agreement for
CTP-656

### Upcoming Events [View all]

Nov 14, 2017 4:15 PM ET 2017 Stifel Healthcare Conference

Nov 16, 2017 8:00 AM ET
Jefferies 2017 London Healthcare Conference

### Financials [View all]

Apr 26, 2017
Proxy Statement (DEF 14A)

Aug 8, 2017 Quarterly Report (10-Q)

May 2, 2017 Quarterly Report (10-Q)